
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The USP prepares for its quinquennial conference in March.
over 21 years ago
Correcting the Courseover 21 years ago
February 2005over 21 years ago
Contract Manufacturers Getting Squeezedover 21 years ago
In the Spotlight-February 2005over 21 years ago
Emerging Analytical Technology: Moving from the Lab to the Lineover 21 years ago
Drug Safety Fears May Limit Reimporting and Shape R&Dover 21 years ago
In Defense of USP Singlet Testing





